在三级护理教学医院,临床药师监测和报告辐射相关不良事件,以达到更好的治疗效果并建议预防措施的观察性研究

Q2 Medicine
Perspectives in Clinical Research Pub Date : 2022-10-01 Epub Date: 2021-08-21 DOI:10.4103/picr.PICR_272_20
Rajesh Hadia, Dhaval Joshi, Trupal Rathod
{"title":"在三级护理教学医院,临床药师监测和报告辐射相关不良事件,以达到更好的治疗效果并建议预防措施的观察性研究","authors":"Rajesh Hadia,&nbsp;Dhaval Joshi,&nbsp;Trupal Rathod","doi":"10.4103/picr.PICR_272_20","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study was conducted to investigate the potential role of clinical pharmacists in monitoring and developing a reporting system of radiation-related adverse events (RRAEs) in cancer patients and provided suggestive measures to prevent RRAEs to achieve a better therapeutic outcome for improving patient health-related quality of life.</p><p><strong>Methodology: </strong>This study was a prospective observational study conducted for a period of 2 years at a private academic oncology teaching care hospital. Patients on radiation therapy or chemoradiation therapy were enrolled and followed by clinical pharmacists on daily basis to identify adverse event(s) if any. Upon identification, adverse events were discussed with concerned radiation oncologists for authentication and graded as defined by the radiation therapy oncology group. Enrolled patients were also followed to ensure if they were provided adequate supportive care for RRAEs.</p><p><strong>Results: </strong>A total of 715 patients were followed during the study period. A total of 422 RRAEs were identified in patients who were on radiation therapy or chemoradiation therapy. The most common reported events were fatigue (<i>n</i> = 64, 15.16%), followed by mucositis (<i>n</i> = 55, 13.03%), diarrhea (<i>n</i> = 37, 8.76%), vomiting (<i>n</i> = 31, 7.34%), gastritis (<i>n</i> = 29, 6.87%), and dryness of the mouth (<i>n</i> = 22, 5.21%). Among the study patients who developed RRAEs, majority (<i>n</i> = 253, 60%) of them received a combination of chemotherapy and radiation therapy and 169 (40%) of 442 patients received radiotherapy alone. Cisplatin weekly monotherapy or cisplatin-based chemotherapy was commonly used pharmacological treatment in patients on chemoradiation therapy. Clinical pharmacists intervened to initiate adequate supportive care for nearly 20% (<i>n</i> = 84) patients.</p><p><strong>Conclusions: </strong>Clinical pharmacists may be contributing to monitoring and development of reporting systems for radiation-related toxicities/RRAEs in cancer patients. Teamwork of clinical pharmacists with radiation oncologists can improve the safety reporting of radiation and can ensure required medical and supportive care to manage RRAEs.</p>","PeriodicalId":20015,"journal":{"name":"Perspectives in Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/97/PCR-13-205.PMC9635345.pdf","citationCount":"1","resultStr":"{\"title\":\"An observational study to monitor and report radiation-related adverse events by a clinical pharmacist to achieve a better therapeutic outcome and suggest preventive measures in a tertiary care teaching hospital.\",\"authors\":\"Rajesh Hadia,&nbsp;Dhaval Joshi,&nbsp;Trupal Rathod\",\"doi\":\"10.4103/picr.PICR_272_20\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study was conducted to investigate the potential role of clinical pharmacists in monitoring and developing a reporting system of radiation-related adverse events (RRAEs) in cancer patients and provided suggestive measures to prevent RRAEs to achieve a better therapeutic outcome for improving patient health-related quality of life.</p><p><strong>Methodology: </strong>This study was a prospective observational study conducted for a period of 2 years at a private academic oncology teaching care hospital. Patients on radiation therapy or chemoradiation therapy were enrolled and followed by clinical pharmacists on daily basis to identify adverse event(s) if any. Upon identification, adverse events were discussed with concerned radiation oncologists for authentication and graded as defined by the radiation therapy oncology group. Enrolled patients were also followed to ensure if they were provided adequate supportive care for RRAEs.</p><p><strong>Results: </strong>A total of 715 patients were followed during the study period. A total of 422 RRAEs were identified in patients who were on radiation therapy or chemoradiation therapy. The most common reported events were fatigue (<i>n</i> = 64, 15.16%), followed by mucositis (<i>n</i> = 55, 13.03%), diarrhea (<i>n</i> = 37, 8.76%), vomiting (<i>n</i> = 31, 7.34%), gastritis (<i>n</i> = 29, 6.87%), and dryness of the mouth (<i>n</i> = 22, 5.21%). Among the study patients who developed RRAEs, majority (<i>n</i> = 253, 60%) of them received a combination of chemotherapy and radiation therapy and 169 (40%) of 442 patients received radiotherapy alone. Cisplatin weekly monotherapy or cisplatin-based chemotherapy was commonly used pharmacological treatment in patients on chemoradiation therapy. Clinical pharmacists intervened to initiate adequate supportive care for nearly 20% (<i>n</i> = 84) patients.</p><p><strong>Conclusions: </strong>Clinical pharmacists may be contributing to monitoring and development of reporting systems for radiation-related toxicities/RRAEs in cancer patients. Teamwork of clinical pharmacists with radiation oncologists can improve the safety reporting of radiation and can ensure required medical and supportive care to manage RRAEs.</p>\",\"PeriodicalId\":20015,\"journal\":{\"name\":\"Perspectives in Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ad/97/PCR-13-205.PMC9635345.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Perspectives in Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/picr.PICR_272_20\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/8/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives in Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/picr.PICR_272_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

目的:本研究旨在探讨临床药师在监测和建立癌症患者辐射相关不良事件(RRAEs)报告系统中的潜在作用,并提供预防RRAEs的建议措施,以达到更好的治疗效果,提高患者健康相关生活质量。方法:本研究是一项前瞻性观察研究,在一家私立学术肿瘤学教学护理医院进行了为期2年的研究。接受放射治疗或放化疗的患者被登记入组,临床药剂师每天对其进行随访,以确定是否有不良事件。识别后,与相关放射肿瘤学家讨论不良事件进行验证,并根据放射治疗肿瘤学组的定义进行分级。还对入选患者进行了随访,以确保他们是否为RRAEs提供了充分的支持性护理。结果:研究期间共随访715例患者。在接受放射治疗或放化疗的患者中,共发现422例RRAEs。最常见的报告事件是疲劳(n = 64, 15.16%),其次是粘膜炎(n = 55, 13.03%)、腹泻(n = 37, 8.76%)、呕吐(n = 31, 7.34%)、胃炎(n = 29, 6.87%)和口干(n = 22, 5.21%)。在研究中发生RRAEs的患者中,大多数(n = 253, 60%)接受了化疗和放疗的联合治疗,442例患者中有169例(40%)接受了单独放疗。顺铂每周一次单药治疗或以顺铂为基础的化疗是放化疗患者常用的药物治疗。临床药师对近20%(84例)患者进行干预,给予充分的支持治疗。结论:临床药师可能有助于癌症患者辐射相关毒性/RRAEs报告系统的监测和发展。临床药剂师与放射肿瘤学家的团队合作可以改善放射安全报告,并确保必要的医疗和支持性护理来管理RRAEs。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An observational study to monitor and report radiation-related adverse events by a clinical pharmacist to achieve a better therapeutic outcome and suggest preventive measures in a tertiary care teaching hospital.

Objectives: This study was conducted to investigate the potential role of clinical pharmacists in monitoring and developing a reporting system of radiation-related adverse events (RRAEs) in cancer patients and provided suggestive measures to prevent RRAEs to achieve a better therapeutic outcome for improving patient health-related quality of life.

Methodology: This study was a prospective observational study conducted for a period of 2 years at a private academic oncology teaching care hospital. Patients on radiation therapy or chemoradiation therapy were enrolled and followed by clinical pharmacists on daily basis to identify adverse event(s) if any. Upon identification, adverse events were discussed with concerned radiation oncologists for authentication and graded as defined by the radiation therapy oncology group. Enrolled patients were also followed to ensure if they were provided adequate supportive care for RRAEs.

Results: A total of 715 patients were followed during the study period. A total of 422 RRAEs were identified in patients who were on radiation therapy or chemoradiation therapy. The most common reported events were fatigue (n = 64, 15.16%), followed by mucositis (n = 55, 13.03%), diarrhea (n = 37, 8.76%), vomiting (n = 31, 7.34%), gastritis (n = 29, 6.87%), and dryness of the mouth (n = 22, 5.21%). Among the study patients who developed RRAEs, majority (n = 253, 60%) of them received a combination of chemotherapy and radiation therapy and 169 (40%) of 442 patients received radiotherapy alone. Cisplatin weekly monotherapy or cisplatin-based chemotherapy was commonly used pharmacological treatment in patients on chemoradiation therapy. Clinical pharmacists intervened to initiate adequate supportive care for nearly 20% (n = 84) patients.

Conclusions: Clinical pharmacists may be contributing to monitoring and development of reporting systems for radiation-related toxicities/RRAEs in cancer patients. Teamwork of clinical pharmacists with radiation oncologists can improve the safety reporting of radiation and can ensure required medical and supportive care to manage RRAEs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Perspectives in Clinical Research
Perspectives in Clinical Research Medicine-Medicine (all)
CiteScore
2.90
自引率
0.00%
发文量
41
审稿时长
36 weeks
期刊介绍: This peer review quarterly journal is positioned to build a learning clinical research community in India. This scientific journal will have a broad coverage of topics across clinical research disciplines including clinical research methodology, research ethics, clinical data management, training, data management, biostatistics, regulatory and will include original articles, reviews, news and views, perspectives, and other interesting sections. PICR will offer all clinical research stakeholders in India – academicians, ethics committees, regulators, and industry professionals -a forum for exchange of ideas, information and opinions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信